Page 1792 - Williams Hematology ( PDFDrive )

1766 Part XI: Malignant Lymphoid Diseases Chapter 107: Myeloma 1767

325. Solomon A, Frangione B, Franklin EC: Bence Jones proteins and light chains of immu- 357. Chandy KG, Stockley RA, Leonard RC, et al: Relationship between serum viscosity
noglobulins. Preferential association of the V lambda VI subgroup of human light and intravascular IgA polymer concentration in IgA myeloma. Clin Exp Immunol 46:
chains with amyloidosis AL (lambda). J Clin Invest 70:453–460, 1982. 653–661, 1981.
326. Zhang SQ, Dong P, Zhang ZL, et al: Renal plasmacytoma: Report of a rare case and 358. Capra JD, Kunkel HG: Aggregation of gamma-G3 proteins: Relevance to the hypervis-
review of the literature. Oncol Lett 5:1839–1843, 2013. cosity syndrome. J Clin Invest 49:610–621, 1970.
327. Reeves WB, Foley RJ, Weinman EJ: Nephrotoxicity from nonsteroidal anti-inflamma- 359. Bichel J, Effersoe P, Gormsen H, et al: Leukemic myelomatosis (plasma cell leukemia);
tory drugs. South Med J 78:318–322, 1985. a review with report of four cases. Acta Radiol 37:196–207, 1952.
328. Grima DT, Airia P, Attard C, et al: Modelled cost-effectiveness of high cut-off haemo- 360. Garcia-Sanz R, Orfao A, Gonzalez M, et al: Primary plasma cell leukemia: Clinical,
dialysis compared to standard haemodialysis in the management of myeloma kidney. immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93:1032–1037,
Curr Med Res Opin 27:383–391, 2011. 1999.
329. Hutchison C, Sanders PW: Evolving strategies in the diagnosis, treatment, and moni- 361. Noel P, Kyle RA: Plasma cell leukemia: An evaluation of response to therapy. Am J Med
toring of myeloma kidney. Adv Chronic Kidney Dis 19:279–281, 2012. 83:1062–1068, 1987.
330. Hutchison CA, Cockwell P, Reid S, et al: Efficient removal of immunoglobulin free light 362. van de Donk NW, Lokhorst HM, Anderson KC, et al: How I treat plasma cell leukemia.
chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Blood 120:2376–2389, 2012.
Nephrol 18:886–895, 2007. 363. Weinstock M, Ghobrial IM: Extramedullary multiple myeloma. Leuk Lymphoma
331. Blade J, Fernandez-Llama P, Bosch F, et al: Renal failure in multiple myeloma: Present- 54:1135–1141, 2013.
ing features and predictors of outcome in 94 patients from a single institution. Arch 364. Bartel TB, Haessler J, Brown TL, et al: F18-fluorodeoxyglucose positron emission
Intern Med 158:1889–1893, 1998. tomography in the context of other imaging techniques and prognostic factors in mul-
332. Kastritis E, Anagnostopoulos A, Roussou M, et al: Reversibility of renal failure in newly tiple myeloma. Blood 114:2068–2076, 2009.
diagnosed multiple myeloma patients treated with high dose dexamethasone-contain- 365. Short KD, Rajkumar SV, Larson D, et al: Incidence of extramedullary disease in patients
ing regimens and the impact of novel agents. Haematologica 92:546–549, 2007. with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on
333. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility extramedullary myeloma. Leukemia 25:906–908, 2011.
and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65:175–181, 366. Barlogie B, Smallwood L, Smith T, et al: High serum levels of lactic dehydrogenase
2000. identify a high-grade lymphoma-like myeloma. Ann Intern Med 110:521–525, 1989.
334. Bjerrum OW, Rygaard-Olsen C, Dahlerup B, et al: The carpal tunnel syndrome and 367. Usmani SZ, Heuck C, Mitchell A, et al: Extramedullary disease portends poor progno-
amyloidosis. A clinical and histological study. Clin Neurol Neurosurg 86:29–32, 1984. sis in multiple myeloma and is over-represented in high-risk disease even in the era of
335. Pratt G, Goodyear O, Moss P: Immunodeficiency and immunotherapy in multiple mye- novel agents. Haematologica 97:1761–1767, 2012.
loma. Br J Haematol 138:563–579, 2007. 368. Varettoni M, Corso A, Pica G, et al: Incidence, presenting features and outcome of
336. Jacobson DR, Zolla-Pazner S: Immunosuppression and infection in multiple myeloma. extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive
Semin Oncol 13:282–290, 1986. patients. Ann Oncol 21:325–330, 2010.
337. Ullrich S, Zolla-Pazner S: Immunoregulatory circuits in myeloma. Clin Haematol 369. Cherng NC, Asal NR, Kuebler JP, et al: Prognostic factors in multiple myeloma. Cancer
11:87–111, 1982. 67:3150–3156, 1991.
338. Campbell JD, Cook G, Robertson SE, et al: Suppression of IL-2-induced T cell prolifera- 370. Chamberlain MC, Glantz M: Myelomatous meningitis. Cancer 112:1562–1567, 2008.
tion and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed 371. Chang H, Sloan S, Li D, et al: Multiple myeloma involving central nervous system: High
by IL-15. J Immunol 167:553–561, 2001. frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 127:280–284, 2004.
339. Cook G, Campbell JD: Immune regulation in multiple myeloma: The host-tumour con- 372. Fassas AB, Spencer T, Sawyer J, et al: Both hypodiploidy and deletion of chromosome
flict. Blood Rev 13:151–162, 1999. 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118:1041–
340. Cook G, Campbell JD, Carr CE, et al: Transforming growth factor beta from multiple 1047, 2002.
myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc 373. Rasche L, Bernard C, Topp MS, et al: Features of extramedullary myeloma relapse: High
Biol 66:981–988, 1999. proliferation, minimal marrow involvement, adverse cytogenetics: A retrospective sin-
341. Gorelik L, Flavell RA: Transforming growth factor-beta in T-cell biology. Nat Rev gle-center study of 24 cases. Ann Hematol 91:1031–1037, 2012.
Immunol 2:46–53, 2002. 374. Sheth N, Yeung J, Chang H: P53 nuclear accumulation is associated with extramedul-
342. Ratta M, Fagnoni F, Curti A, et al: Dendritic cells are functionally defective in multiple lary progression of multiple myeloma. Leuk Res 33:1357–1360, 2009.
myeloma: The role of interleukin-6. Blood 100:230–237, 2002. 375. Wang SY, Hao HL, Deng K, et al: Expression levels of phosphatase and tensin homolog
343. Rawstron AC, Davies FE, Owen RG, et al: B-lymphocyte suppression in multiple mye- deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple
loma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell myeloma and their relationship to clinical stage and extramedullary infiltration. Leuk
precursors. Br J Haematol 100:176–183, 1998. Lymphoma 53:1162–1168, 2012.
344. Mills KH, Cawley JC: Abnormal monoclonal antibody-defined helper/suppressor 376. Raanani P, Shpilberg O, Ben-Bassat I: Extramedullary disease and targeted therapies for
T-cell subpopulations in multiple myeloma: Relationship to treatment and clinical hematological malignancies—Is the association real? Ann Oncol 18:7–12, 2007.
stage. Br J Haematol 53:271–275, 1983. 377. Bataille R, Durie BG, Grenier J, et al: Prognostic factors and staging in multiple mye-
345. Ogawara H, Handa H, Yamazaki T, et al: High Th1/Th2 ratio in patients with multiple loma: A reappraisal. J Clin Oncol 4:80–87, 1986.
myeloma. Leuk Res 29:135–140, 2005. 378. Gassmann W, Pralle H, Haferlach T, et al: Staging systems for multiple myeloma: A
346. Mariani S, Coscia M, Even J, et al: Severe and long-lasting disruption of T-cell receptor comparison. Br J Haematol 59:703–711, 1985.
diversity in human myeloma after high-dose chemotherapy and autologous peripheral 379. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of
blood progenitor cell infusion. Br J Haematol 113:1051–1059, 2001. measured myeloma cell mass with presenting clinical features, response to treatment,
347. Mozaffari F, Hansson L, Kiaii S, et al: Signalling molecules and cytokine production in T and survival. Cancer 36:842–854, 1975.
cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 380. Bataille R, Grenier J, Sany J: Beta-2-microglobulin in myeloma: Optimal use for staging,
124:315–324, 2004. prognosis, and treatment—a prospective study of 160 patients. Blood 63:468–476, 1984.
348. Kay NE, Leong TL, Bone N, et al: Blood levels of immune cells predict survival in 381. Garewal H, Durie BG, Kyle RA, et al: Serum beta 2-microglobulin in the initial staging
myeloma patients: Results of an Eastern Cooperative Oncology Group phase 3 trial for and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 2:51–57,
newly diagnosed multiple myeloma patients. Blood 98:23–28, 2001. 1984.
349. Xie J, Wang Y, Freeman ME 3rd, et al: Beta 2-microglobulin as a negative regulator of 382. Child JA, Norfolk DR, Cooper EH: Serum beta 2-microglobulin in myelomatosis. Br J
the immune system: High concentrations of the protein inhibit in vitro generation of Haematol 63:406–407, 1986.
functional dendritic cells. Blood 101:4005–4012, 2003. 383. Resnick D KM: Plasma cell dyscrasias, in Bone and Joint Imaging. Elsevier: Canada, 2004.
350. Vesole DH, Oken MM, Heckler C, et al: Oral antibiotic prophylaxis of early infection 384. Collins CD: Multiple myeloma. Cancer Imaging 4:S47–S53, 2004.
in multiple myeloma: A URCC/ECOG randomized phase III study. Leukemia 26: 385. Singh J, Fairbairn KJ, Williams C, et al: Expert radiological review of skeletal surveys
2517–2520, 2012. identifies additional abnormalities in 23% of cases: Further evidence for the value of
351. Miralles GD, O’Fallon JR, Talley NJ: Plasma-cell dyscrasia with polyneuropathy. The myeloma multi-disciplinary teams in the accurate staging and treatment of myeloma
spectrum of POEMS syndrome. N Engl J Med 327:1919–1923, 1992. patients. Br J Haematol 137:172–173, 2007.
352. Waldenstrom JG, Adner A, Gydell K, et al: Osteosclerotic “plasmocytoma” with 386. Wahlin A, Holm J, Osterman G, et al: Evaluation of serial bone X-ray examination in
polyneuropathy, hypertrichosis and diabetes. Acta Med Scand 203:297–303, 1978. multiple myeloma. Acta Med Scand 212:385–387, 1982.
353. Preston FE, Cooke KB, Foster ME, et al: Myelomatosis and the hyperviscosity syn- 387. Collins CD: Problems monitoring response in multiple myeloma. Cancer Imaging
drome. Br J Haematol 38:517–530, 1978. 5:S119–S126, 2005.
354. Pruzanski W, Watt JG: Serum viscosity and hyperviscosity syndrome in IgG multiple 388. Ludwig H, Fruhwald F, Tscholakoff D, et al: Magnetic resonance imaging of the spine in
myeloma. Report on 10 patients and a review of the literature. Ann Intern Med 77: multiple myeloma. Lancet 2:364–366, 1987.
853–860, 1972. 389. Ghanem N, Lohrmann C, Engelhardt M, et al: Whole-body MRI in the detection of
355. Somer T: Rheological basis of the hyperviscosity syndrome of plasma cell dyscrasias: A bone marrow infiltration in patients with plasma cell neoplasms in comparison to the
review. Bibl Anat 13:105–106, 1975. radiological skeletal survey. Eur Radiol 16:1005–1014, 2006.
356. Stone MJ, Bogen SA: Evidence-based focused review of management of hyperviscosity 390. Baur-Melnyk A, Buhmann S, Becker C, et al: Whole-body MRI versus whole-body
syndrome. Blood 119:2205–2208, 2012. MDCT for staging of multiple myeloma. AJR Am J Roentgenol 190:1097–1104, 2008.

Kaushansky_chapter 107_p1733-1772.indd 1767 9/21/15 12:35 PM